Dake Andrew W, Sora Nicoleta D
Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, South Carolina.
Division of Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, Charleston, South Carolina.
Am J Med Sci. 2016 Apr;351(4):361-5. doi: 10.1016/j.amjms.2016.01.020. Epub 2016 Feb 2.
Cardiovascular disease is the most common cause of morbidity and mortality in patients with diabetes and the major source of cost in the care of diabetes. Treatment of dyslipidemia with cholesterol-lowering medications has been shown to decrease cardiovascular events. However, available guidelines for the treatment of dyslipidemia often contain significant differences in their recommendations.
Lipid guidelines from National Cholesterol Education Program Adult Treatment Panel III, American Association of Clinical Endocrinologists, American Diabetes Association and American Heart Association/American College of Cardiology were reviewed. In addition a literature review was performed using PubMed to research diabetic peculiarities to the topic of lipids.
Summarized within this article are the aforementioned, commonly-used guidelines as they relate to diabetes, as well as information regarding the diabetic phenotype of dislipidemia and the association between statins and new-onset diabetes.
While the multitude of guidelines and the differences between them may contribute to confusion for practitioners, they are best viewed as tools to help tailor appropriate treatment plans for individual patients.
心血管疾病是糖尿病患者发病和死亡的最常见原因，也是糖尿病护理费用的主要来源。使用降胆固醇药物治疗血脂异常已被证明可减少心血管事件。然而，现有的血脂异常治疗指南在其建议方面往往存在显著差异。
对美国国家胆固醇教育计划成人治疗小组III、美国临床内分泌医师协会、美国糖尿病协会以及美国心脏协会/美国心脏病学会的血脂指南进行了审查。此外，还使用PubMed进行了文献综述，以研究糖尿病在血脂方面的特殊性。
本文总结了上述常用指南与糖尿病的相关性，以及有关血脂异常的糖尿病表型和他汀类药物与新发糖尿病之间关联的信息。
虽然众多指南及其之间的差异可能会给从业者带来困惑，但最好将它们视为帮助为个体患者制定合适治疗方案 的工具。
